2227 GMT - Healius's recent performance by its pathology business underwhelms Citi. Healius indicates profitability of Pathology division in 1H would be broadly in line with the same period a year earlier. That implies some A$4 million Ebit, well below Citi's A$14 million forecast and an even bigger miss to consensus hopes. It also comes despite a 5.9% improvement in revenue in FY 2025 so far. Healius says it has faced labor cost rises and is investing to keep its revenue growing. "Healius believes its share has stabilized in the last six months, albeit it seems to have come at a cost to profitability," says analyst Mathieu Chevrier. Citi retains a sell call on Healius's stock. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
November 17, 2024 17:27 ET (22:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.